How long will it take the Department of Finance to question the reimbursement of non-facilitated medicines? If a new medicine does not provide a substantial clinical benefit and does not address an unmet need, why should it be reimbursed in a timely fashion, or at all? This discussion inside government is inevitable.
Formal consideration of rationing now a matter of time
June 19, 2019 Latest NewsCommentNews of the DayLatest Video
New Stories
-
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News